Harry Paul Erba, MD, PhD

Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address harry.erba@duke.edu

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Education and Training

  • Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
  • Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
  • Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
  • Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
  • Ph.D., Stanford University, 1988
  • M.D., Stanford University School of Medicine, 1988

Publications

Ustun, Celalettin, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, et al. “Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study..” Leukemia, May 9, 2019. https://doi.org/10.1038/s41375-019-0477-x.

PMID
31073153
Full Text

Stock, Wendy, Selina M. Luger, Anjali S. Advani, Jun Yin, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, et al. “A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403..” Blood 133, no. 14 (April 4, 2019): 1548–59. https://doi.org/10.1182/blood-2018-10-881961.

PMID
30658992
Full Text

Medeiros, Bruno C., Megan Othus, Martin S. Tallman, Zhuoxin Sun, Hugo F. Fernandez, Jacob M. Rowe, Hillard M. Lazarus, et al. “The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)..” Leuk Res 78 (March 2019): 29–33. https://doi.org/10.1016/j.leukres.2019.01.007.

PMID
30673620
Full Text

Othus, Megan, Elihu H. Estey, Guillermo Garcia-Manero, Brent L. Wood, Derek L. Stirewalt, John E. Godwin, James K. Weick, et al. “Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials..” Leukemia 33, no. 2 (February 2019): 554–58. https://doi.org/10.1038/s41375-018-0274-y.

PMID
30315233
Full Text

Othus, Megan, Mikkael A. Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Eli Estey. “Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies..” Leukemia 33, no. 2 (February 2019): 371–78. https://doi.org/10.1038/s41375-018-0275-x.

PMID
30315234
Full Text

Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL..” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.

PMID
30501481
Full Text

Halpern, Anna B., Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, et al. “Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms..” Leukemia 32, no. 11 (November 2018): 2352–62. https://doi.org/10.1038/s41375-018-0135-8.

PMID
29720734
Full Text

Jamy, Omer, Sejong Bae, Luciano J. Costa, Harry P. Erba, and Nikolaos Papadantonakis. “Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow..” Leuk Res 74 (November 2018): 64–67. https://doi.org/10.1016/j.leukres.2018.09.014.

PMID
30300822
Full Text

Fathi, Amir T., Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, et al. “A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML..” Blood 132, no. 11 (September 13, 2018): 1125–33. https://doi.org/10.1182/blood-2018-03-841171.

PMID
30045838
Full Text

Pages